The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Even modest losses of true skeletal muscle, particularly if accompanied by reductions in strength or power, may have outsized consequences for function and healthspan
On the other hand, tirzepatides stomach-related problems tend to decrease just a few weeks after starting
Some people successfully: Lose fat Improve metabolic health Maintain muscle Increase strength at the same time
This matters for GLOW because multi-peptide blends should not be treated like ordinary shelf products
Consistently using the same spot can lead to skin irritation, scarring, or hard lumps under the skin